Estrogen receptors (ER) and androgen receptors (AR) function as key drivers in many breast and prostate cancers, respectively, and their ligand-dependent activity underlies the success of endocrine therapies (e.g., anti-estrogens in ER+ breast cancer and anti-androgens in prostate cancer). This evidence concerns the gene ESR1 and Familial prostate cancer.